Welcome

Welcome to
CLN2 Meetings

This website has been developed as a scientific and educational resource for healthcare professionals in EMEA region interested to learn more about CLN2 Disease, its current clinical care and management along with the latest CLN2 research findings. ​

Log in Register

Are you a healthcare professional?

The information provided on this website is intended for use by healthcare professionals practicing in the Europe, Middle East and Africa – EMEA region. The dissemination of this information may be subject to different medical and regulatory requirements across the EMEA countries.​

I confirm that I am a healthcare professional practicing in EMEA region I am a member of the public

All the content about BRINEURA® (cerliponase alfa) currently available on CLN2 Meetings platform has been approved and is consistent with the latest and most updated version of EU SmPC.​

CLN2 Meetings’ content is periodically reviewed by BioMarin and may be subject to changes to assure compliance with EMEA general regulations around on promotion of prescription medicines.

You can always find out the most updated version of Brineura’s abbreviated prescribing information (API) under the menu option "API" at the top bar navigation.​

Close

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.